<DOC>
	<DOCNO>NCT00406419</DOCNO>
	<brief_summary>This study evaluate efficacy safety ocrelizumab , compare placebo , combination methotrexate patient active rheumatoid arthritis inadequate response methotrexate . Patients randomize receive placebo , 200mg intravenous ocrelizumab 500mg i.v . ocrelizumab Days 1 15 . A repeat course i.v . treatment administer Weeks 24 26 . All patient receive 7.5mg - 25mg/week concomitant methotrexate stable dose . The anticipated time study treatment 1-2 year . Target sample size 1000 .</brief_summary>
	<brief_title>A Study Ocrelizumab Compared Placebo Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment ( STAGE )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Inclusion criterion : Adult patient , ≥18 year age Rheumatoid arthritis ≥ 3 month Inadequate clinical response methotrexate dose 7.525mg/week ≥ 12 week Exclusion criterion : Rheumatic autoimmune disease inflammatory joint disease , RA Prior receipt biologic therapy RA Concurrent treatment DMARD ( methotrexate )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>anti-CD20</keyword>
	<keyword>stage</keyword>
	<keyword>CD20</keyword>
	<keyword>RA</keyword>
</DOC>